CONSULTANT HAEMATOLOGIST
A/Prof Chris Barnes
MBBS FRACP FRCPA
Associate Professor Chris Barnes received medical training at Monash University before training in paediatric haematology and oncology at the Royal Children’s Hospital. He completed clinical and laboratory haematology training at the Royal Melbourne Hospital.
Chris has trained overseas at the Hospital for Sick Children, and St Michaels Hospital, Toronto, Canada where he trained as a clinical fellow in haemostasis and thrombosis.
Practice Interests
Chris has a particular interest in paediatric haematology and the diagnosis and management of non – malignant haematological conditions including thrombosis and bleeding disorders.
Chris uses evidence-based medicine in his approach in the diagnosis and management of patients. Where evidence or guidelines are lacking, Chris relies on his extensive clinical experience and network of national and international colleagues to identify best practice and applies this in a patient centric approach.
Practice Locations
A/Prof Chris Barnes consults across two locations in Melbourne:
Coburg and Parkville where he sees paediatric patients at Melbourne Paediatric Specialists at the Children’s, located in the Royal Children’s Hospital precinct.
279 Moreland Road
Coburg VIC 3058
Tel: 03 9386 5527
Fax: 03 9383 7185
Email: admin@melbournehaematology.com.au
Melbourne Paediatric Specialists
The Royal Children’s Hospital
Suite 3.7, Level 3
48 Flemington Road
Parkville VIC 3052
Hospital Accreditation
Clinical Interests Include:
Anaemia, neutropenia & thrombocytopeniaAnticoagulation managementAssessment of bleeding or bruisingBone marrow failure disordersDiagnosis & management of Von Willebrand's diseaseElevated serum ferritin or iron overloadHaematological aspects of menorrhagiaHaemochromatosisHaemoglobinopathyInvestigation of prothrombotic abnormalities (thrombophilia)Iron deficiencyManagement of DVT or PE (thrombosis)Obstetric haematologyPaediatric haematologyTransfusion medicine
Updated: September 2025
Extended Profile
Associate Professor Chris Barnes
– Key Research, Journal & Book Publications, Presentations &/or Awards
Principle investigator of all of the following clinical trials
- BYOND 9HB01EXT (Biogen): An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B
- ASPIRE 8HA01EXT (Biogen): An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and treatment of bleeding episodes in previously treated subjects with Hemophilia A
- PUP A 997HA306 (Biogen): An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A
- PUP B 998HB303 (Biogen): An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
- PATHFINDER 2 (Novo Nordisk): A Multi-national Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC 0129-0000-1003 when administered for Treatment and Prophylaxis of Bleeding in patients with Haemophilia A
- PATHFINDER 3 (Novo Nordisk): Efficacy and Safety of NNC 0129-0000-1003 during Surgical Procedures in Patients with Haemophilia A
- PARADIGM 6 NN7999-3895 (Novo Nordisk): Safety and Efficacy of nonacog beta pegol (N9-GP) in previously untreated Patients with Haemophilia B
- PATHFINDER 6 NN7088-3908 (Novo Nordisk): Safety and Efficacy of turoctocog alfa pegol (N8-GP) in previously untreated Patients with Haemophilia A
- CSL FIX (CSL Behring): Phase III Open-label, Multicenter, Pharmacokinetics, Safety, and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Children with Hemophilia B
- CSL FIX EXTENSION (CSL Behring): A Phase III Open-label, Multicenter, Pharmacokinetics, Safety, and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Children with Hemophilia B
- CSL FVIII (CSL Behring): A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population with Severe Hemophilia A
- CSL FVIII EXTENSION (CSL Behring): A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagualation Factor VIII (rVIII-SingleChain, CSL 627) in Subjects with Severe Hemophilia
- ITP- ROMIPLOSTIM (AMGEN): A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenia Pediatric Subjects with Immune Thrombocytopenia (ITP)
- Explorer 8 Explorer 8 – Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors
- MO41787 (HAVEN 7) – A phase IIIb, multicenter, open-label, single-arm study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous emicizumab in patients from birth.
- An Open-Label Study In Pediatric (<18 Years Of Age), Severe Hemophilia A Participants (Coagulation Factor Activity <1%) With Or Without Inhibitors Or Moderately Severe To Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With Or Without Inhibitors Comparing 12 Months Of Historical Standard Treatment To Marstacimab Prophylaxis
Book Chapters
- Barnes, C and Ashley, D. Cancer in children, In Paediatric Chiropractics 2000. Editor N Davies Churchill-Livingstone Chapter 17 243 – 264. 2012
- Rizzi M and Barnes, C A diagnostic approach to a child with a thrombosis in Sickkids Handbook of Paediatric Thormbosis and Haemostasis Editors Blanchette, V Breakley V and Revel – Vilk, S Karger 2016
- Iorio, A Barnes, C Vedovati, MC Favaloro, EJ Thrombophilia in cerebral vein thrombosis. In Handbook on Cerebral Vein Thrombosis. Front Neurol Neurosci. Basel. Karger. 2008 vol 23 pp 55 – 76
- Saxon, B and Barnes, C Abnormal bleeding and clotting. Practical Paediatrics 7th Edition, Elsevier
- Natesiriniku R, Souza LLE, Barnes C, Blanchette V, James P. von Willebrand Disease. third Edition of the SickKids (Hospital for Sick Children, Toronto) Handbook of Pediatric Thrombosis and Hemostasis
Selected Journal Publications
- Barnes C, Deidun D, Hynes K, Monagle P. Alopecia and dalteparin: a previously unreported association. Blood. 2000;96(4):1618-9.
- Barnes C, Rudzki Z, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure. Haemophilia. 2000;6(6):693-5.
- Barnes C, Berkowitz R, Curtis N, Waters K. Aspergillus laryngotracheobronchial infection in a 6-year-old girl following bone marrow transplantation. Int J Pediatr Otorhinolaryngol. 2001;59(1):59-62.
- Barnes C, Brewin T, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report. Haemophilia. 2001;7(4):439-40.
- Barnes C, Monagle P. Haemostatic changes following the modified Fontan procedure. Thrombosis and haemostasis. 2001;86(5):1341; author reply 2.
- Barnes C, Sexton M, Sizeland A, Tiedemann K, Berkowitz RG, Waters K. Laryngo-pharyngeal carcinoma in childhood. Int J Pediatr Otorhinolaryngol. 2001;61(1):83-6.
- Barnes C, Downie P, Chalkiadis G, Camilleri S, Monagle P, Waters K. Sedation practices for Australian and New Zealand paediatric oncology patients. J Paediatr Child Health. 2002;38(2):170-2.
- Barnes C, Ignjatovic V, Newall F, Carlin J, Ng F, Hamilton S, Ashley D, Waters K, Monagle P. Change in serum procalcitonin (deltaPCT) predicts the clinical outcome of children admitted with febrile neutropenia. British Journal of Haematology. 2002;118(4):1197-8.
- Barnes C, Newall F, Higgins S, Carden S, Monagle P. Perinatal management of patients at high risk of homozygous protein C deficiency. Thrombosis and haemostasis. 2002;88(2):370-1.
- Barnes C, Newall F, Monagle P. Post-thrombotic syndrome. Arch Dis Child. 2002;86(3):212-4.
- Barnes C, Newall F, Monagle P. Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. Support Care Cancer. 2002;10(3):256-7; author reply 60-1.
- Barnes C, Monagle P, McNamara J. Velcroholism. J Paediatr Child Health. 2003;39(5):392.
- Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopenia in children. J Paediatr Child Health. 2003;39(4):289-92.
- Newall F, Barnes C, Savoia H, Campbell J, Monagle P. Warfarin therapy in children who require long-term total parenteral nutrition. Pediatrics. 2003;112(5):e386.
- Barnes C, Gerstle JT, Freedman MH, Carcao MD. Clostridium septicum myonecrosis in congenital neutropenia. Pediatrics. 2004;114(6):e757-60.
- Barnes C, Hogan C, Antippa P, Tuckfield A. Penetrating injury to the heart in a patient with haemophilia. Haemophilia. 2004;10(1):101.
- Barnes C, Newall F, Furmedge J, Mackay M, Monagle P. Arterial ischaemic stroke in children. J Paediatr Child Health. 2004;40(7):384-7.
- Barnes C, Newall F, Furmedge J, Mackay M, Monagle P. Cerebral sinus venous thrombosis in children. J Paediatr Child Health. 2004;40(1-2):53-5.
- Barnes C, Newall F, Harvey AS, Monagle P. Thrombophilia interpretation in childhood stroke: a cautionary tale. J Child Neurol. 2004;19(3):218-9.
- Barnes C, Wong P, Egan B, Speller T, Cameron F, Jones G, Ekert H, Monagle P. Reduced bone density among children with severe hemophilia. Pediatrics. 2004;114(2):e177-81.
- Ignjatovic V, Barnes C, Newall F, Hamilton S, Burgess J, Monagle P. Point of care monitoring of oral anticoagulant therapy in children: comparison of CoaguChek Plus and Thrombotest methods with venous international normalised ratio. Thrombosis and haemostasis. 2004;92(4):734-7.
- Barnes C, Blanchette V, Canning P, Carcao M. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med. 2005;15(2):145-50.
- Barnes C, Newall F, Ignjatovic V, Wong P, Cameron F, Jones G, Monagle P. Reduced bone density in children on long-term warfarin. Pediatr Res. 2005;57(4):578-81.
- Barnes C, Deveber G. Prothrombotic abnormalities in childhood ischaemic stroke. Thrombosis research. 2006;118(1):67-74.
- Barnes C, Rivard GE, Poon MC, Teitel J, Pai M, Kern M, Blanchette VS, Carcao M, Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of C. Canadian multi-institutional survey of immune tolerance therapy (ITT) — experience with the use of recombinant factor VIII for ITT. Haemophilia. 2006;12(1):1-6.
- Kelsey G, Monagle P, Barnes C. Delayed diagnosis of congenital factor IX deficiency (Christmas disease) in a girl with Turner’s Syndrome. Clin Lab Haematol. 2006;28(5):355-6.
- Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, De Rosa L, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Roy N, Rowlands S. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thrombosis and haemostasis. 2006;95(2):362-72.
- Newall F, Wallace T, Crock C, Campbell J, Savoia H, Barnes C, Monagle P. Venous thromboembolic disease: a single-centre case series study. J Paediatr Child Health. 2006;42(12):803-7.
- Price V, Barnes C, Canning P, Blanchette V, Greenberg M. Immune thrombocytopenia following successful treatment of cancer in children. Pediatric blood & cancer. 2006;46(3):372-6.
- Barnes C, Blanchette V, Lillicrap D, Mann K, Stain AM, Leggo J, Hilliard P, Carcao M. Different clinical phenotype in triplets with haemophilia A. Haemophilia. 2007;13(2):202-5.
- Davis A, Barnes C. Thrombotic thrombocytopenic purpura in childhood: an uncommon but life-threatening cause of thrombocytopenia. J Paediatr Child Health. 2007;43(9):640-2.
- Newall F, Browne M, Savoia H, Campbell J, Barnes C, Monagle P. Assessing the outcome of systemic tissue plasminogen activator for the management of venous and arterial thrombosis in pediatrics. J Pediatr Hematol Oncol. 2007;29(4):269-73.
- Thomas S, Herbert D, Street A, Barnes C, Boal J, Komesaroff P. Attitudes towards and beliefs about genetic testing in the haemophilia community: a qualitative study. Haemophilia. 2007;13(5):633-41.
- Broderick CR, Herbert RD, Latimer J, Barnes C, Curtin JA, Monagle P. Estimation of transient increases in bleeding risk associated with physical activity in children with haemophilia. BMC Blood Disord. 2008;8:2.
- Iorio A, Barnes C, Vedovati MC, Favaloro EJ. Thrombophilia and cerebral vein thrombosis. Front Neurol Neurosci. 2008;23:55-76.
- Monagle P, Newall F, Barnes C, Savoia H, Campbell J, Wallace T, Crock C. Arterial thromboembolic disease: a single-centre case series study. J Paediatr Child Health. 2008;44(1-2):28-32.
- Dunkley SM, Russell SJ, Rowell JA, Barnes CD, Baker RI, Sarson MI, Street AM, Australian Haemophilia Centre Directors O. A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders. Med J Aust. 2009;191(8):460-3.
- Gelbart B, Barnes C. Severe haemophilia and extreme prematurity–a case report. Haemophilia. 2009;15(1):352-4.
- Gordon A, Barnes C, Mackay M. Paediatric stroke: the need for interdisciplinary models of care. J Paediatr Child Health. 2009;45(5):243-5.
- Barnes C, Davis A, Furmedge J, Egan B, Donnan L, Monagle P. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX. Haemophilia. 2010;16(5):840-1.
- Radhakrishnan K, Goel H, Barnes C. Vacuolated lymphocytes-a diagnostic clue. Eur J Haematol. 2010;85(5):460-1.
- Sexton A, Furmedge J, Barnes C, Cheetham G, Wallace J, Savarirayan R. Clinical significance of two mutations in the factor IX gene in a family with haemophilia B. Haemophilia. 2010;16(2):374-6.
- Stokes IC, Downie PA, Wood EM, Bowden DK, Monagle PT, Barnes CD. Hyperhaemolysis in sickle cell disease–an unusual and potentially life-threatening complication. Med J Aust. 2010;192(5):281-2.
- Howman R, Barnes C, Curtin J, Price J, Robertson J, Russell S, Seldon M, Suppiah R, Teague L, Barrese G. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE(R), in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia. 2011;17(3):463-9.
- Long B, Anderson V, Jacobs R, Mackay M, Leventer R, Barnes C, Spencer-Smith M. Executive function following child stroke: the impact of lesion size. Dev Neuropsychol. 2011;36(8):971-87.
- Long B, Spencer-Smith MM, Jacobs R, Mackay M, Leventer R, Barnes C, Anderson V. Executive function following child stroke: the impact of lesion location. J Child Neurol. 2011;26(3):279-87.
- Alexander M, Barnes C, Barnett P. Prospective audit of patients with haemophilia: bleeding episodes and management. J Paediatr Child Health. 2012;48(2):177-9.
- Broderick CR, Herbert RD, Latimer J, Barnes C, Curtin JA, Mathieu E, Monagle P, Brown SA. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452-9.
- Brown SA, Barnes C, Curtin J, Dunkley S, Ockelford P, Phillips J, Rowell J, Smith M, Tran H, Hematology working g. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011. Intern Med J. 2012;42(11):1243-50.
- McQuilten ZK, Barnes C, Zatta A, Phillips LE, Haemostasis Registry Steering C. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics. 2012;129(6):e1533-40.
- Percy MJ, Barnes C, Crighton G, Leventer RJ, Wynn R, Lappin TR. Methemoglobin reductase deficiency: novel mutation is associated with a disease phenotype of intermediate severity. J Pediatr Hematol Oncol. 2012;34(6):457-60.
- Barnes C. Importance of pharmacokinetics in the management of hemophilia. Pediatric blood & cancer. 2013;60 Suppl 1:S27-9.
- Furmedge J, Lima S, Monagle P, Barnes C, Newall F. ‘I don’t want to hurt him.’ Parents’ experiences of learning to administer clotting factor to their child. Haemophilia. 2013;19(2):206-11.
- Teoh Y, Greenway A, Savoia H, Monagle P, Roy J, Barnes C. Hospitalisations for sickle-cell disease in an Australian paediatric population. J Paediatr Child Health. 2013;49(1):68-71.
- Yeoh ZH, Furmedge J, Ekert J, Crameri J, Curtis N, Barnes C. Central venous access device-related infections in patients with haemophilia. J Paediatr Child Health. 2013;49(3):242-5.
- Barnes C, Brown SA, Curtin J, Dunkley S. When is enough…enough? Developing consensus of definition of failure of immune tolerance induction in patients with haemophilia and inhibitors. Haemophilia. 2014;20(4):e275-9.
- Barnes C, Curtin J, Brown S, Suppiah R, Price J, Russell S, Prasad R, Seldon M. Benchmarking the management of children with haemophilia in Australia. J Paediatr Child Health. 2014;50(12):1032-3.
- Orme LM, Babl FE, Barnes C, Barnett P, Donath S, Ashley DM. Outpatient versus inpatient IV antibiotic management for pediatric oncology patients with low risk febrile neutropenia: a randomised trial. Pediatric blood & cancer. 2014;61(8):1427-33.\
- Brown SA, Phillips J, Barnes C, Curtin J, McRae S, Ockelford P, Dunkley S (2015). Challenges in hemophilia care in Australia and New Zealand.. Current Medical Research & Opinion, 31(11), 1985-91. https://dx.doi.org/10.1185/03007995.2015.1082990
- Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13(6):967-77.
- Cooper MS, Randall M, Rowell M, Charlton M, Greenway A, Barnes C. Congenital Methemoglobinemia Type II-Clinical Improvement with Short-Term Methylene Blue Treatment. Pediatric blood & cancer. 2016;63(3):558-60.
- Harper P, Favaloro EJ, Curtin J, Barnes C, Dunkley S. Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data. Drugs in context. 2016;5:212292.
- Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Makipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment. British Journal of Haematology. 2017;179(2):298-307.
- Pasi KJ, Fischer K, Ragni M, Nolan B, Perry DJ, Kulkarni R, Ozelo M, Mahlangu J, Shapiro AD, Baker RI, Bennett CM, Barnes C, Oldenburg J, Matsushita T, Yuan H, Ramirez-Santiago A, Pierce GF, Allen G, Mei B. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and haemostasis. 2017;117(3):508-18.
- Alhucema P, Furmedge J, Campbell S & Barnes C (2018). Pyogenic sacroiliitis and haemophilia-a duo not often considered. Haemophilia, 24(2), e60-e61. https://dx.doi.org/10.1111/hae.13412
- Nolan B, Mahlangu J, Pabinger I, Young G, Konkle BA, Barnes C, Oldenburg J (2020). Recombinant factor viii fc fusion protein for the treatment of severe haemophilia a: final results from the aspire extension study.. Haemophilia, 26(3), 494-502. https://dx.doi.org/10.1111/hae.13953
- Chan AK, Alamelu J, Barnes C, Chuansumrit A, Garly ML, Meldgaard RM & Young G (2020). Nonacog beta pegol (n9-gp) in hemophilia b: first report on safety and efficacy in previously untreated and minimally treated patients.. Research And Practice In Thrombosis And Haemostasis, 4(7), 1101-1113. https://dx.doi.org/10.1002/rth2.12412
- Blanchette VS, Zunino L, Grassmann V, Barnes C, Carcao MD, Curtin J, Blatny J (2021). A practical, one-clinic visit protocol for pharmacokinetic profile generation with the advate mypkfit dosing tool in severe hemophilia a subjects.. Thrombosis & Haemostasis, 121(10), 1326-1336. https://dx.doi.org/10.1055/a-1376-0970
- Shapiro AD, Kulkarni R, Ragni MV, Chambost H, Mahlangu J, Oldenburg J, Barnes C, Pasi KJ (2023). Post hoc longitudinal assessment of the efficacy and safety of recombinant factor ix fc fusion protein in hemophilia b.. Blood Advances, 7(13), 3049-3057. https://dx.doi.org/10.1182/bloodadvances.2022009230
- Wheeler AP, Abraham A, Barnes C, Brown Frandsen R, d’Oiron R, Eichler H, Castaman G (2025). Real-world unmet needs of patients with haemophilia a and haemophilia b with or without inhibitors: end-of-study results from the explorer6 non-interventional study. Haemophilia, 2025 May 5. doi: 10.1111/hae.70051. Epub ahead of print.
- Panozzo B, Ramnarain J, Chen S, Yuen HLA, Tatarczuch M, Vilcassim S, Leow CCY, Barnes, C (2025). A critical analysis of Cellavision systems in a the modern hematology laboratory. Am J Clin Path (In press)
Invited Presentations
2017
- “How we use the Australian Bleeding disorders registry” Invited presenter, Haemophilia Foundation Australia Conference 2017
- “Changing Face of Prophylaxis in Haemophilia” Invited presenter and chair, Haemophilia Foundation Australia Shire Educational Symposium 2017
- “Haemophilia Management in Australia” CSL Advisory Board meeting, 2017
2016
- “Not just a nose bleed – What is HHT” GCPE Conference 2016
- “Non Compliant patients – my approach” Australian Haemophilia Centre Directors Organisation education symposium, 2016
- “Haemophilia and other bleeding disorders – implications for dentists” Royal Children’s Hopsital Dental Department Education Lecture Series 2016
- “PNH – the paediatric haematologists perspective” Alexion Education Seminar 2016
- “Hereditary haemolysis” Alexion Education Seminar 2016
- “How we will be treating inhibitors in the future”Biogen Haemophilia Medical Education Melbourne 2016
- “Paediatric haematology – normal and abnormal” Haemostasis weekend Melbourne 2016
- “Current situation and issues in the treatment of haemophilia in Asia Pacific Area”” Asia Pacific Thrombosis and Haemostasis Conference
2015
- “Comprehensive care – the journey” Haemophilia Foundation Australia Conference 2015
- “Purpose of prophylaxis treatment after injury in patients with haemophilia” Haemophilia Foundation of Australia Conference 2015
- “Not grey – it is black and white; role of ultrasound diagnosis in patients with haemarthrosis” Haemophilia Foundation of Australia conference Pfizer education symposium 2015
- “What is happening with a joint bleed” Invited presenter, Haemophilia Foundation Australia NovoNordisk Symposium 2015
- “Royal Children’s Hospital experience with MyPKFit pharmokinetic program”Baxalta eduation seminar 2015
2014
- “I bruise easily” Australian Pre-analytical network national conference 2014
- “Management of a bleeding patient” Blood school 2014
- “Joint health in haemophilia – can we do more?” Pfizer sponsored satellite symposium at the World Federation of Haemophilia Congress 2014
- “Outcome measures in haemophilia” International Network Paediatric Haemophilia 2014
- “Australian Framework for management of bleeding disorders” World Federation of Haemophilia Congress 2014
- “Modes of prophylaxis and Outcome measures” South Australian Haematology Interest Group 2014
- “Outcome measures in haemophilia” ANZ haemophilia forum 2014
- “Update of haemophilia management in Australia” Biogen education seminar 2014
- “The increasing importance of pharmacokinetics in dosing factor concentrates” Australian haemophilia centre director’s education seminar 2014
2013
- “Platelets in paediatrics – a haematologists approach to congential thrombocytopena”Walter and Eliza Hall institute education seminar 2013
- “Bleeding management and home treatment (prophyalxis) in inhibitor patients” Malaysia paediatric haemophilia symposium 2013“Haemophilia practices in Australia” Asia Pacific Haemophilia Forum 2013
2009
- “Caring for patients with inhibitors” Haemophilia Foundation Conference 2009
- “Using evidence and experience – the benefits of benchmarking” Haemophilia Foundation Conference 2009
- “HAA blood film morphology session” HAA Confernce 2009
- “Inhibitors in Australia” HSANZ presentation 2009
2008
- “Von Willebrand disease in children” ACHDO Education Day 2008
- “Paediatric haemophilia care in Australia” Asia Pacific Haemophilia Advisory Board 2008
- “Immune tolerance induction for patients with inhibitors to factor IX” Bari International Conference 2008
2007
- “Treatment of patients with inhibitors and immune tolerance” Haemophlia Foundation of Australia Conference 2007
- “…And what about the future?” Haemophlia Foundation of Australia Conference 2007
- “Bleeding in the neonate” Austin Hospital education seminar 2007
- “Haemophilia care in the Asia Pacific region” Asia Pacific Haemophilia Advisory Board 2007
- “Management of pregnancy in carrier of haemophilia” Bayer Educational Seminar 2007
- “Treatment of haemophilia in Australia” Asia Pacific Haemophilia Advisory Board 2007
- “Haemophilia 2007” Launceston Education Seminar 2007
- “Forward thinking in haemophilia management” Haemophilia Foundation Victoria 2007
2006
- “Assessment of the child with potential non accidental injury” Paediatric Update RCH 2006
- “Haemophilia update” Haemophilia Foundation Victoria Carriers workshop 2006
2005
- “How I treat von Willebrand disease” Australain Haemophlia Centre Directors Organisation Education Day 2005
2004
- “Haemophilia 2004 and the role of genetic testing” MRCI 2004
- “Pharmacokinetics of factor VIII Kogenate FS in children – factors affective recovery and elimination” Hospital for Sick Children Resident Clinical Research Competition 2004
- “Canadian Multi-institutional retrospective survey of immune tolerance therapy” ACHDC education seminar 2004
Funded Grants
External Peer Reviewed Funded Grants
- Government of Victoria, Department Health and Community Services New Technologies Grant 1997/8 “Stem Cell Supported Chemotherapy at the Royal Children’s Hospital”
- Government of Victoria, Department Health and Community Services New Technologies Grant 1998/9 “Stem Cell Supported Chemotherapy at the Royal Children’s Hospital”
- NHMRC Research Fellowship “Developmental Haemostasis” 2000
- Heart Kids Victoria Research Grant 2001“Monitoring the antiplatelet effect of aspirin in children with the Platelet Function Analyser (PFA – 100)”.
- Haemophilia Foundation of Australia Grant “Head injury in children with haemophilia – predictors of clinical outcome”
- Haemophilia Foundation of Australia Grant “Thrombin generation, the role of hyperfibrinolysis (levels of Thrombin Activatable Fibrinolysis Inhibitor; TAFI) and levels of Tissue Factor Pathway Inhibitor (TFPI) in children with severe Haemophilia: correlation to clinical outcomes”.
Internal Peer Reviewed Funded Grants
- Murdoch Children’s Research Institute Grant 2000 “The role of Procalcitonin in discriminating bacterial sepsis in febrile neutropenic children”
- Murdoch Children’s Research Institute Grant 2001“A cross sectional survey of bone density in children with severe haemophilia”
Industry Funded Grants
- Bayer Industry supported grant “Rapidpoint, point of care monitoring in children”, 2002
- Baxter Bioscience Haemostasis Fellowship Grant, The Hospital For Sick Children, Toronto, Canada
